spinout
Galapagos Splitting Into Two Companies, Cutting 300 Jobs, Altering Gilead Licensing Deal
The changes will result in one company focused exclusively on cancer cell therapies and another on strategic transactions to build a pipeline of innovative medicines.
TORL BioTherapeutics' CLDN6-Targeting Antibody-Drug Conjugate Demonstrates Encouraging Early Results
Premium
Phase I data presented at ESMO suggested that TORL-1-23 may have particularly strong activity in CLDN-positive advanced ovarian cancer.
BridgeBio Launches Precision Oncology Spinoff With $200M in Funding
BridgeBio Oncology Therapeutics will launch with three precision oncology programs targeting KRAS and PI3K.
The firm launched earlier this month, aiming to test an autologous CAR T-cell therapy first in patients with DIPG, then in all CNS metastases.
The lead investigators have also spun out a company, Isabl, aiming to make the approach available to the broader community.